IL-6 Inhibitor Shows Promise in Diabetic Macular Edema

(MedPage Today) -- DENVER -- Targeting an inflammatory pathway in diabetic macular edema (DME), in addition to angiogenesis, led to greater improvement in visual acuity and retinal anatomy, a randomized trial showed. Single-agent ranibizumab...
Source
MedPage Today
Opens original article in a new tab



